Persistence of Biologic Disease-modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis: An analysis of the South Korean National Health Insurance Database

This study examined and compared the persistence of adalimumab, etanercept, infliximab, or abatacept as first- and subsequent-line treatment for rheumatoid arthritis in the South Korean clinical practice.

Source: Seminars in Arthritis and Rheumatism - August 29, 2017 Category: Rheumatology Authors: Min-Young Lee, Ju-Young Shin, Sun-Young Park, Donguk Kim, Hoon-Suk Cha, Eui-Kyung Lee Source Type: research